Homma M, Tanaka A, Hino K, Takamura H, Hirano T, Oka K, Kanazawa M, Miwa T, Notoya Y, Niitsuma T, Hayashi T
Department of Pharmaceutical Sciences, Institute of Clinical Medicine, University of Tsukuba, Amakubo, Tsukuba, Ibaraki, Japan.
Metabolism. 2001 Jul;50(7):801-4. doi: 10.1053/meta.2001.24213.
11beta-hydroxysteroid dehydrogenase (11beta-HSD), an enzyme regulating mineralocorticoid like action of glucocorticoid, oxidizes active cortisol to inactive cortisone. Impaired activity of this enzyme is associated with apparent mineralocorticoid excess (AME) syndrome and is characterized by hypertension and hypokalemia. Recent investigations suggest the presence of hypertensive subjects with low activity of 11beta-HSD. The blood concentration ratio of cortisone/cortisol reflects the overall conversion of cortisol to cortisone and may be an index to assess the systemic activity of 11beta-HSD. We evaluated the peripheral blood concentration ratio of cortisone/cortisol as a possible marker to identify subjects with hypertension thought to represent impaired 11beta-HSD activity. We compared this ratio in healthy subjects and patients with diabetes mellitus (DM) or chronic renal failure (CRF). Peripheral blood samples were collected from 69 healthy subjects, 44 DM, and 36 CRF patients in the morning (9:00 to 11:00 AM). Twenty-six DM patients (59%) and 32 CRF patients (89%) met the criteria for having hypertension. Serum cortisol and cortisone concentrations were determined by high performance liquid chromatography (HPLC). All values for serum cortisone and cortisol levels were within the normal range. Serum cortisone/cortisol ratio in the healthy subjects was distributed with a range of 0.113 to 0.494 (median, 0.243). Compared with healthy subjects, DM and CRF patients had significantly low (P <.01) serum cortisone/cortisol levels (median, 0.188 [range, 0.092 to 0.313] in DM and 0.088 [range, 0.031 to 0.140] in CRF). Bimodal distribution of cortisone/cortisol, found in DM patients with hypertension, represented high- and low-ratio groups around the border of the ratio 0.2. Kidney function, DM duration, and complications varied between the high- and low-ratio groups. The low ratio group (<0.2), whose 11beta-HSD activity was considered low, had an increase in blood urea nitrogen (BUN) levels and experienced nephropathy, neuropathy, retinopathy, and prolonged DM duration when compared with the group with a ratio greater than 0.2. The data suggest that the serum cortisone/cortisol ratio reflects the change in 11beta-HSD activity and is dependent kidney function. This is a possible marker to evaluate glucocorticoid excess hypertension observed in DM and CRF patients.
11β-羟类固醇脱氢酶(11β-HSD)是一种调节糖皮质激素盐皮质激素样作用的酶,它将活性皮质醇氧化为无活性的可的松。该酶活性受损与表观盐皮质激素增多症(AME)综合征相关,其特征为高血压和低钾血症。最近的研究表明存在11β-HSD活性低的高血压患者。可的松/皮质醇的血浓度比值反映了皮质醇向可的松的总体转化情况,可能是评估11β-HSD全身活性的一个指标。我们评估了外周血可的松/皮质醇浓度比值,将其作为一种可能的标志物,以识别被认为存在11β-HSD活性受损的高血压患者。我们比较了健康受试者、糖尿病(DM)患者和慢性肾衰竭(CRF)患者的这一比值。于上午(9:00至11:00)采集了69名健康受试者、44名DM患者和36名CRF患者的外周血样本。26名DM患者(59%)和32名CRF患者(89%)符合高血压标准。采用高效液相色谱法(HPLC)测定血清皮质醇和可的松浓度。血清可的松和皮质醇水平的所有值均在正常范围内。健康受试者的血清可的松/皮质醇比值分布范围为0.113至0.494(中位数为0.243)。与健康受试者相比,DM患者和CRF患者的血清可的松/皮质醇水平显著降低(P<.01)(DM患者中位数为0.188[范围为0.092至0.313],CRF患者中位数为0.088[范围为0.031至0.140])。在患有高血压的DM患者中发现的可的松/皮质醇双峰分布,代表了比值0.2边界附近的高比值组和低比值组。高比值组和低比值组之间的肾功能、DM病程和并发症各不相同。与比值大于0.2的组相比,比值低的组(<0.2),其11β-HSD活性被认为较低,血尿素氮(BUN)水平升高,且出现肾病、神经病变、视网膜病变,DM病程延长。数据表明血清可的松/皮质醇比值反映了11β-HSD活性的变化,且依赖于肾功能。这是评估DM和CRF患者中观察到的糖皮质激素过多性高血压的一种可能标志物。